EUCTR2014-000586-45-BE
Active, Not Recruiting
Phase 1
Oxytocin-based pharmacotherapy for Autism Spectrum Disorders:Investigating the neural and behavioral effects of a promising interventionapproach - Oxytocin study
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Young male adults with Autism Spectrum Disorders (18-30 years)
- Sponsor
- KU Leuven
- Enrollment
- 40
- Status
- Active, Not Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Young male adult participants with autism spectrum disorder will be
- •recruited mainly from the Expertise Centrum Autisme (ECA) of the UZ
- •Leuven, Belgium.
- •Participants are selected when diagnosed with ASD by a
- •multidisciplinary team of experienced clinicians as defined by the DSMIV\-
- •TR (or DSM\-V) criteria (Diagnostic and Statistical Manual of Mental
- •Disorders). In addition to the DSM\-criteria, the Developmental
- •Dimensional Diagnostic instrument (3DI, David Skuse) and the Autism
- •Diagnostic Observation Schedule (ADOS) will be adopted as diagnostic
- •Participants within an age\-range of 18\-30 will be included.
Exclusion Criteria
- •Participants will be excluded based on the following criteria:
- •(i) associated psychiatric or neurological disorders (e.g. ADHD),
- •(ii) use of psychotropic medication,
- •(iii) any contraindication to neuroimaging research as assessed with the
- •MRI screening list (see below)
- •MRI contraindications
- •pacemaker, implanted defibrillator, ear implant / a cochlear implant,
- •insulin or implanted pump, a neurostimulator or VP shunt, any metallic
- •object in the eyes (metallic fragments)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Intranasal Oxytocin for Autism Spectrum Disorder and Comorbid Severe Intellectual Disabilities:open-label studyAutism spectrum disorder severe intellectual disabilitiesJPRN-UMIN000024339ational Hospital Organization Hizen Psychiatric Center7
Completed
N/A
Intranasal Oxytocin for Autism Spectrum Disorder and Comorbid Severe Intellectual Disabilities:Open-label long term studyAutism Spectrum Disorder Severe intellectual disabilitiesJPRN-UMIN000028650ational Hospital Organization Hizen Psychiatric Center3
Completed
Phase 4
Neural and Behavioral Effects of Oxytocin in Autism Spectrum DisordersAutism Spectrum DisordersNCT02940574KU Leuven40
Completed
N/A
Intranasal Oxytocin for the Treatment of Autism Spectrum DisordersAutism Spectrum DisordersNCT01337687Montefiore Medical Center19
Completed
Phase 2
Single Dose Intranasal Oxytocin and Cognitive Effects in AutismAutism Spectrum DisordersNCT02493426University of Minnesota27